ArticleEndocrine2026
Conditional survival disparities and determinants in Urban-Rural patients with papillary thyroid carcinoma.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundUrban-rural disparities are significant determinants of cancer outcomes; however, population-based long-term dynamic survival differences in papillary thyroid carcinoma (PTC) remain unclear. Utilizing the US Surveillance, Epidemiology, and End Results (SEER) database, this study aimed to unveil the spatiotemporal evolution of urban-rural disparities in PTC through conditional survival analysis for the first time, and to identify modifiable influencing factors, thereby providing evidence for precision public health strategies.
methodsWe conducted a retrospective cohort study based on the US SEER-18 database (2000–2019), with urban-rural classification defined according to the Office of Management and Budget standards. Survival disparities were assessed using the Kaplan-Meier method, and multivariate adjustments were performed using Cox proportional hazards models. Conditional survival analysis (CS(y|x) = S(x + y)/S(x)) was applied to quantify the dynamic evolution of survival probabilities. Stratified analyses based on metastatic status and surgical intervention were performed to elucidate the sources of heterogeneity in these disparities.
resultsThis study analyzed 170,505 PTC patients. Multivariable analysis confirmed age ≥ 55, male sex, advanced tumor stage, and non-married status as independent risk factors for disease-specific death, with surgery being a strong protective factor. Notably, advanced tumor stage, especially distant metastasis, posed a greater mortality risk for rural patients. Survival analysis demonstrated a superior long-term prognosis for urban patients, with a 20-year disease-specific survival rate of 97.5% versus 97.1% for rural patients. The survival gap widened over time. Death hazard rates were higher in rural patients within the first decade after diagnosis, exhibiting a distinct dynamic pattern. While conditional survival improved with longer elapsed time in both groups, urban patients established a sustained advantage after 6 years post-diagnosis.Stratified analyses revealed that the urban–rural survival disparity was most pronounced among males, patients with distant metastasis, and those not undergoing surgery. Importantly, undergoing surgery significantly narrowed this prognostic gap.
conclusionThis study employs conditional survival analysis to reveal that urban-rural survival disparities in PTC patients exhibit dynamic time-varying characteristics. The core mechanism lies in the inequality of healthcare resource accessibility, which leads to gaps in the long-term management of high-risk patients. This provides critical evidence for implementing targeted regional intervention strategies.
Indexed as
Identifiers
41920412What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.